R&D channel feed – Endpoints News

R&D channel feed

Alzheon’s amyloid-targeting pill fails another Phase 3 study in Alzheimer’s

Last month

Q&A: Lundbeck’s head of R&D on letting ‘biology speak’ in neuroscience

Last month

Cartesian reveals long-term mid-stage data for cell therapy in myasthenia gravis

Last month

Rhythm touts Phase 3 win for rare obesity drug in people with brain damage

Last month

Novavax’s held-up approval package may signal warning for Covid vaccine makers

Last month

Secretive Chinese startup begins first-ever clinical trial of circular RNA therapy

Last month

Arvinas touts healthy volunteer data for Parkinson's disease PROTAC

Last month

Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid

Last month

Roche plans Phase 3 for its latest Alzheimer’s drug attempt after unveiling more early data

Last month

Another TIGIT trial fails as BeiGene scraps Phase 3 drug

Last month

Novartis’ Chinook-originated kidney disease drug gets accelerated approval

Last month

Sarepta, Roche pause Elevidys trials in Europe following patient death

Last month

Edgewise's heart drug shows promise in Phase 2 trial

Last month

Axsome reports Phase 3 depression fail for Sunosi

Last month

Compass Therapeutics touts trial success in biliary tract cancer, but more data are needed

Last month

Gubra’s AbbVie-partnered amylin looks competitive with Zealand’s in early trial

Last month

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Last month

RNA editing startup raises $155M to bring liver and lung disease therapy into clinic

Last month

Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia

Last month

Tenaya to lay off about one-third of staff, reveals heart gene therapy data

Last month

Vaxcyte's Phase 2 pneumococcal vaccine data disappoint Wall Street

Last month

Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer

Last month

Merck’s PAH drug cuts risk of serious events by 76% in trial stopped for efficacy

Last month

AstraZeneca’s cholesterol pill is set for Phase 3, but lags behind Merck rival

Last month

First page Previous page 2 3 456 7 8 Next page Last page